Vigil’s TREM2-Targeted Alzheimer’s Treatment Shows Early Promise, Moves On to Phase II
In a possible redemption for the TREM2 space in Alzheimer’s disease, Vigil Neuroscience announced positive early-stage data Thursday for its...
Phase
Cassava’s Shares Plunge as Alzheimer’s Drug Fails Phase III
After promising to set the record straight on the potential of simufilam to help with Alzheimer’s disease, Cassava Sciences reported...
